Healthy Male Clinical Trial
Choline alfoscerate(L-alfa glycerylphosphorylcholine) is a natural compound found in the
brain and breast. Choline alfoscerate contains 40.8% of choline and has a produrig structure
and separated by a precursor of choline and nerve cell membrane precursor of acetylcholine
glycerophosphate. Choline alfoscerate Colin normalization of nerve pathways, nerve cell
membrane play and acetylcholine receptor function secondary symptoms caused by
cerebrovascular deficiency and indirectly through activation of metabolism, has a
degenerative effect on the brain organic mental syndrome.
Currently marketed oral choline alfoscerate received a geriatric cognitive impairment,
secondary symptoms and degeneration, or soft capsule is authorized to prescription drugs for
degenerative brain organic mental syndrome caused by cerebrovascular deficiency. Gliatilin
soft capsules containing 400 mg per 1 capsule 2-3 times one days're supposed to take when
considering optimal convenience and efficiency of the drug in patients with the development
of sustained release formulations that can be maintained for a long period of time, a
certain concentration is required. Accordingly, the modern drug by reducing the frequency of
administration a day circuit is to develop a sustained release formulation of choline
alfoscerate HT-003 600 mg medication compliance for the purpose of raising. 2 tablets at a
time (600 mg x 2) can be taken one day to 1200 mg is required by taking.
Therefore, for the development of sustained release formulation, the test in healthy adult
male volunteers targets choline alfoscerate soft capsule formulation of 400mg 3 times per 1
day and sustained-release tablet 600mg 2time per 1 day, pharmacokinetic properties and
safety of a single dose should be evaluated when compared.
n/a
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04135898 -
A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects
|
Phase 1 | |
| Recruiting |
NCT05849311 -
Phase I Trial of Envafolimab for Healthy Male Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT06105255 -
A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553
|
Phase 1 | |
| Completed |
NCT01651234 -
A Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC4401C in Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT01359618 -
Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart
|
Phase 1 | |
| Completed |
NCT02395913 -
Compare Safety and Pharmacokinetic Properties of Surfolase Capsule(Acebrophylline 100mg) and Surfolase CR(200mg)
|
Phase 1 | |
| Completed |
NCT06194500 -
A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants
|
Phase 1 | |
| Completed |
NCT05202912 -
Food Effect Study of IDX-1197 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04828265 -
Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects
|
Phase 1 |